Work

Clade I mpox vaccination: strategies for deployment and evaluation

Year: 2025

Type: article

Abstract: Clade I mpox continues to spread in Central Africa with no sign of abating,1 however very few doses of vaccine have been deployed. Mpox vaccination strategies using either of the licenced vaccines, MVA-BN and LC16m8, are being drawn up across 17 African countries and vaccination has begun in the Democratic Republic of Congo (DRC), Rwanda and Nigeria.2 Clinical studies during the rollout could deliver much-needed data about the effectiveness of the vaccine against clade I mpox. Choosing the right study design is fundamental.

Source: EBioMedicine

DOI: 10.1016/j.ebiom.2025.105890

Authors: Caitlin Pley, Jasmina Panovska-Griffiths, Robert Hinch, Chris Wymant, Lucie Abeler-Dörner, Deogratius Ssemwanga, Ronald Moses Galiwango, M. Kate Grabowski, Francesco Di Lauro, Luca Ferretti, James Hay, Marc Lipsitch, Jake Dunning, Joseph Kagaayi, Pontiano Kaleebu, Christophe Fraser

Institutions: University of Oxford, UK Health Security Agency, MRC/UVRI & LSHTM Uganda Research Unit, Uganda Virus Research Institute, Rakai Health Sciences Program, Johns Hopkins University, Harvard University, Makerere University

Language: English

Topic: Poxvirus research and outbreaks

Subfield: Virology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $5,780

Funders: Coalition for Epidemic Preparedness Innovations, University of Oxford, Precursory Research for Embryonic Science and Technology

OpenAlex ID: W4413371795

FWCI:

Cites: 6

Cited by:

Related to: 10